Israeli hospitals provide evidence-based Crohn’s disease treatment through a multidimensional approach involving biological therapies, specialized diets, and stem cell research. Standard care features advanced diagnostics like capsule endoscopy and personalized biologics. Leading centers including Sourasky Medical Center and Hadassah Medical Center utilize multidisciplinary teams for complex cases.
- Biological therapies: Standard use of Infliximab, Adalimumab, and newer IL-23 inhibitors like Risankizumab.
- Nutritional intervention: Application of the locally developed Crohn’s Disease Exclusion Diet (CDED).
- Surgical expertise: Minimally invasive bowel resections and stricturoplasty performed by experienced colorectal surgeons.
- Innovative options: Access to stem cell therapy and bacteriotherapy for refractory disease cases.
Bookimed Expert Insight: While many countries follow basic step-up protocols, Israeli specialists like Dr. Maharshak Nitzan at Sourasky Medical Center integrate unconventional evidence-based methods like bacteriotherapy. Data shows these high-volume centers manage over 400,000 patients annually. This massive patient flow allows doctors to refine niche treatments, such as fecal bacteria research, which are rarely available in standard European or North American clinics.
Patient Consensus: Patients note that Israeli gastroenterologists often prioritize exhausting all medical and biological options before recommending surgery. They emphasize that while finding the right maintenance regimen takes trial and error, access to updated biosimilars happens relatively quickly.
